🔗 Share this article

A shadow market for unlicensed weight-loss drugs is being driven by social media fitness personalities and sellers on messaging platforms, based on new investigations.

Investigational Treatment Acquiring Traction Online

The experimental drug, which remains in clinical trials, is being promoted by online personalities for its supposed fat-burning properties. Viewers are urged to message these profiles directly for supplier links, while also obtaining promotional offers.

Active Trade on Messaging Platforms

Additionally, a robust trade exists on messaging services, where communities with numerous of members share “before and after” photos, injection guides and assertions of rapid British shipping. Sellers market the drug there before redirecting customers to WhatsApp for transactions.

Learning About The Experimental Drug

Retatrutide is an investigational injectable created by US drugmaker Eli Lilly. The drug affects three gut hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Preliminary studies suggest it could help individuals reduce up to 25% of their body weight. Referred to as the “triple G”, the drug is being hailed digitally as the successor to Ozempic.

Healthcare Professionals Voice Concerns

However, physicians and chemists have cautions that the sale of what remains an unapproved medication in the United Kingdom is worrisome and could result in users injecting products of unknown origin.

Several experts said the demand for the experimental drug could be connected to the increasing price of licensed weight loss products such as Mounjaro.

Legal Status and Implementation

Selling retatrutide on social media or messaging apps is illegal in the UK, as it is an unapproved medication that must not be marketed or distributed for personal consumption under the Human Medicines Regulations 2012.

Some influencers try to circumvent the regulations by referring to the drug as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a restricted drug, but advertising and distribution can still breach medicines, advertising, and consumer regulations, risking fines, legal action or imprisonment.

Platform Response and Material Elimination

According to the social media company, the platform has taken down violative material and banned associated hashtags and query recommendations. The organization stated it was committed to maintaining the service secure and investing in strengthening compliance measures.

Online Marketplace Activities

Research also found communities with up to 9,000 participants marketing retatrutide using Telegram's built-in discovery tool, which functions like a online catalog. Typing “retatrutide” immediately brings up channels with numerous of users, populated with photos of weight loss, glowing reviews and detailed guides for preparing or administering at home.

After minutes of entering one community, a vendor shared contact information, where the majority of transactions take place. The seller sent an instruction manual and guaranteed shipping within two days. When asked whether the product was genuine, one seller said: “You can’t be sure.” Another provided a image of a supposed laboratory certificate. Not one asked about weight, health issues or past usage.

Item Information and Pricing

Within these groups, posts display black plastic packages with postal service labels, claiming to contain fresh supplies. One communication read: “It took eight of us to load them this morning.”

Buyers can select between dry substance containers, mixed at home with sterile water, or ready-to-use pens typically sold at £160 for 20mg. When questioned how long a pen should be used, vendors give conflicting responses ranging from a several days to “depends on your body”.

Platform Moderation and Safety Actions

A representative for Telegram stated it regularly moderated harmful content on its platform including content that encouraged the “misuse of controlled medications”. The organization noted that it eliminated “millions of pieces of harmful content each day”.

Medical Expert Warnings

“People are administering substances they cannot confirm. Although the research behind this drug is valid, these digital versions may not contain what they claim,” stated Jason Murphy, the director of pharmaceutical services at Chemist4U.

A medical professional of Asda Online Doctor connected the increase in demand to current price rises for approved slimming medications such as Mounjaro. “With costs increasing, patients are using online platforms. But counterfeit treatments are highly risky. You can’t be certain what’s inside or whether the environment they were produced in was clean,” she explained.

Her staff has already encountered individuals injured by personal administration from unverified sources. “We recognize the disappointment, but buying from messaging apps or WhatsApp is gambling with your well-being,” said Wyllie. “These materials could be contaminated or improperly measured.”

Manufacturer Position

A representative from Eli Lilly said the substance was in third stage research studies and had not been evaluated or authorized by any government authority globally. “Consequently at this time no one can market [it] for human use,” they said, noting that any item “falsely representing itself as a company investigational product not yet authorized … may expose users to potentially significant health risks”.